FGEN — FibroGen Inc
NASDAQ · Healthcare · Biotechnology
FibroGen Inc (FGEN) is a biotechnology company listed on NASDAQ. It is led by Thane Wettig, based in 350 Bay Street, San Francisco, CA, United States, 94133, with about 225 employees. FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Latest reported FGEN revenue for 2025-09-30 was $1.1M. Net income was $197.7M. Revenue was down 20.2% from 2025-06-30 to 2025-09-30. FGEN currently screens at market cap $39.3M.
Use this FGEN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FGEN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FGEN SEC filings page. Lician reads the product cache first so this HTML stays unique to FibroGen Inc even when a live quote feed is slow.
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FGEN Key Statistics
Market Cap
$39.28M
P/B Ratio
53.83
EPS
-$0.48
Revenue
$29.62M
Net Income
-$47.58M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-36.7%
Profit Margin
-160.6%
Employees
225
FGEN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $29.62M | $46.80M | $140.73M | $235.31M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$47.58M | -$284.23M | -$293.65M | -$290.02M |
| EPS (Diluted) | -$0.48 | -$2.92 | -$3.14 | -$3.14 |
Total Assets
$214.53M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$50.48M
Operating Cash Flow
-$138.00M
Free Cash Flow
$0.00
FibroGen Inc Company Information
- CEO & Director
- Thane Wettig
- Headquarters
- 350 Bay Street, San Francisco, CA, United States, 94133
- Website
- www.fibrogen.com
- Phone
- 415 978 1200
- IPO / Founded
- 2014-11-14
- Sector
- Healthcare
- Industry
- Biotechnology